Artificial Antigen-Presenting Cell for Stable T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies, such as dendritic cell-based treatments, face limitations in inducing strong antigen-specific T cell responses, resulting in weak clinical outcomes in cancer patients, highlighting the need for effective shelf-stable pharmaceutical compositions that can activate antigen-specific T cells.
Innovation Solution
Development of pharmaceutical compositions comprising polymeric particles conjugated with anti-CD28 antibodies and antigen-presenting complexes, including HLA molecules, to provide co-stimulatory signals and present antigens effectively, enhancing antigen-specific T cell activation and expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell-based immunotherapy is used to activate T cells, then antigen-specific immune response is induced, but clinical response remains weak due to insufficient T cell activation
Solution Approach 1:
The patent combines multiple essential T cell activation signals into a single artificial antigen-presenting cell platform. The aAPC integrates MHC-antigen complexes for TCR engagement, CD28 co-stimulatory ligands for secondary signaling, and cytokines for T cell proliferation and differentiation. This merging of multiple activation requirements into one unified platform resolves the contradiction by providing all necessary signals simultaneously, thereby strengthening T cell activation while maintaining reliable antigen-specificity.
Solution Approach 2:
The artificial antigen-presenting cell employs a composite structure combining polymeric or liposomal particles with conjugated biological molecules including MHC molecules, antibodies, cytokines, and co-stimulatory ligands. This composite design allows simultaneous delivery of multiple immunological signals that work synergistically to enhance T cell activation strength while preserving antigen-specific recognition, thus improving both productivity and reliability of the immune response.
2Adaptability or versatility
If personalized dendritic cell therapy is administered to each patient, then antigen-specificity is maintained, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent segments the immunotherapy into modular components: standardized aAPC platforms with fixed MHC and co-stimulatory molecules, and interchangeable antigen-specific components. Different antigen peptides or MHC-antigen complexes can be swapped on the same aAPC platform to target different tumors or diseases. This segmentation maintains antigen-specificity for different indications while using a common manufacturing platform, thereby reducing overall manufacturing complexity and enabling scalability.
Solution Approach 2:
The artificial antigen-presenting cell platform is designed with universal features including standardized MHC class I and class II molecules, CD28 co-stimulatory ligands, and multiple cytokine options that can accommodate various antigen specificities. This universal design allows the same basic platform to be used across different cancer types and disease indications by simply changing the antigen component, thus maintaining adaptability while significantly simplifying manufacturing compared to fully personalized approaches.
3Reliability
If dendritic cells are harvested and activated ex vivo, then antigen presentation capability is enhanced, but treatment stability and shelf-life are reduced
Solution Approach 1:
The patent employs artificial antigen-presenting cells based on stable polymeric or liposomal particles that can be manufactured, stored, and shipped under standard pharmaceutical conditions. These synthetic platforms replace fragile primary dendritic cells that require complex ex vivo culture and have limited shelf-life. The aAPCs maintain stable antigen presentation capability throughout storage and transport, then deliver sustained T cell activation upon administration, thus improving both reliability and duration of action.
Solution Approach 2:
The artificial antigen-presenting cell creates a synthetic copy of the essential functional features of natural dendritic cells without using live cells. The aAPC replicates the key functions of antigen presentation via MHC molecules and co-stimulation via CD28 ligands in a stable, non-living platform. This copying approach preserves the antigen presentation capability needed for T cell activation while eliminating the stability and shelf-life limitations of primary dendritic cells.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.